Src kinase pathway inhibitors (University of North Carolina)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameSrc kinase pathway inhibitors (University of North Carolina)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitorsTyrosine-protein kinase SRC inhibitors
TargetsTyrosine-protein kinase 2Tyrosine-protein kinase SRC
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of North Carolina, Greensboro
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of North Carolina, Greensboro
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A